Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, September 17, 2009
Wed, September 16, 2009
Revolutions Medical Corp.: Revolutions Medical Provides Five-Year Revenue Guidance
MOUNT PLEASANT, SC--(Marketwire - September 16, 2009) - Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (
-- 2010E: $14.8 million -- 2011E: $40.9 million -- 2012E: $75.1 million -- 2013E: $115.5 million -- 2014E: $154.5 million
"On the eve of mass production of our flagship Rev Vac safety syringe we are pleased to offer five-year revenue guidance -- the financial roadmap to a potential high growth future," stated Company President Tom O'Brien. "We believe that our products possess distinct competitive advantages that should lead to rapid market penetration, creating strong 2010 revenue traction that could nearly triple in 2011. By 2014 we believe that we will have achieved a five-year compound annual growth rate of 80%.
"We anticipate a very bright future for Revolutions Medical, and we are excited to be at the cusp of a dramatic commercial inflection point. After four tireless years in development, Revolutions Medical stands ready to meet the world."
Revenue projections are dependent on the Company receiving the capital necessary to begin mass production of its Rev Vac safety syringe in Q4 2009, and achieve a first product ship date of June 2010.
To be added to the Revolutions Medical investor email list, please email [ justin.davis@cirrusfc.com ] with RMCP in the subject line.
About Revolutions Medical Corporation ([ www.revolutionsmedical.com ])
Revolutions Medical's products include the Rev Vac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter. Revolutions Medical also provides software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D and automatic segmentation of images.
FORWARD-LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.
